However, the company's main activity is the manufacture of medicine. Sanofi's treatments focus on rare diseases, multiple sclerosis, cancer and diabetes, as well as autoimmune, infectious and cardiovascular diseases. Thus, the pharmaceutical sector generates four-fifths of the group's total turnover. The group's flagship product, Lantus, a long-term insulin, generates 15 percent of the group's total revenues of nearly 40 billion euros.
About 45 percent of the group's 106,000 employees are active in Europe. Most of the staff work in the pharmaceutical sector, while about 15,000 people are employed in the vaccine division.
Vaccine sales amounted to more than 5 billion euros in 2018. Sanofi Pasteur, the group's vaccines division, is one of the world's leaders in this field. From its global headquarters in Lyon, Sanofi Pasteur markets more than one billion doses of vaccines against influenza, polio, pertussis, meningitis, pneumonia, as well as travel vaccines each year. As a result, the group is responsible for annually generating vaccines for 500 million people worldwide.
Recently, the group launched the very first dengue fever vaccine. Produced in France and authorized since 2015 in several countries affected by dengue fever, such as Brazil, Mexico and the Philippines, Dengvaxia generated approximately 55 million euros in 2016.